Welcome to our dedicated page for Avid Bioservices news (Ticker: CDMO), a resource for investors and traders seeking the latest updates and insights on Avid Bioservices stock.
Avid Bioservices, Inc. (NASDAQ: CDMO) is a distinguished contract manufacturing organization (CMO) that specializes in the development and production of biopharmaceutical products. As a subsidiary of Peregrine Pharmaceuticals, Inc., Avid Bioservices offers unique expertise in the manufacturing of monoclonal antibodies, recombinant proteins, and enzymes using mammalian cell culture.
The company excels in providing Current Good Manufacturing Practices (CGMP) compliant process development and manufacturing services. These services range from early-stage development to full-scale commercial production, making Avid Bioservices a key partner for biotechnology and biopharmaceutical industries.
One of the company's recent achievements includes securing a partnership with CIRM-funded programs, granting access to Avid’s suite of world-class CGT CDMO services to support clinical development activities. This collaboration underscores the company’s commitment to advancing biopharmaceutical innovations.
Core Services:
- Monoclonal Antibody Development
- Recombinant Protein Production
- Enzyme Manufacturing
- CGMP Clinical Manufacturing
- Commercial Manufacturing
Avid Bioservices is renowned for its comprehensive development and manufacturing capabilities, which ensure a seamless transition from concept to commercialization. The company’s robust financial condition and strategic partnerships further bolster its position as a leader in the biopharmaceutical manufacturing sector.
By focusing on high-quality production standards and maintaining strong industry relationships, Avid Bioservices continues to play a pivotal role in the biopharmaceutical landscape, driving forward significant advancements in therapeutic development.
For more updates and relevant information about the company’s performance, recent events, and developments, please visit our latest news section.
Avid Bioservices, Inc. (NASDAQ: CDMO) will participate in two investor conferences with Nick Green, the president and CEO, as a key speaker. The company aims to enhance patient lives through biologics development and manufacturing services for biotech and pharma firms.
FAQ
What is the current stock price of Avid Bioservices (CDMO)?
What is the market cap of Avid Bioservices (CDMO)?
What does Avid Bioservices, Inc. specialize in?
What are some of the core services provided by Avid Bioservices?
What is the significance of Avid Bioservices’ partnership with CIRM-funded programs?
Is Avid Bioservices a publicly-traded company?
What sets Avid Bioservices apart from other contract manufacturing organizations?
Who is the parent company of Avid Bioservices, Inc.?
What types of clients does Avid Bioservices serve?
What stages of development can Avid Bioservices support?
How does Avid Bioservices maintain its high production standards?
Where can I find the latest news and updates about Avid Bioservices?
